4D MOLECULAR THERAPEUT

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

17 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

24 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

08 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

06 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

04 Jun 2024 07:00:01 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conference

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

4DMT Announces Presentations at ARVO 2024 Annual Meeting

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

12 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

06 Feb 2024 22:27:14 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

05 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

03 Feb 2024 16:00:00 By Nasdaq GlobeNewswire

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

23 Jan 2024 07:00:00 By Nasdaq GlobeNewswire